ABCL688

About AbCellera

AbCellera's mission is to build a technology-driven biotech capable of repeatedly beating the odds to deliver breakthrough antibody medicines. The company achieved a landmark proof-of-concept through its partnership with Eli Lilly on bamlanivimab for COVID-19, validating its platform's speed and efficacy. Its current strategy represents a pivotal shift from a pure-play technology licensor to an integrated drug developer, leveraging its proprietary platform to build a wholly-owned pipeline of first-in-class and best-in-class assets, while maintaining a portfolio of royalty-bearing partnerships.

Therapeutic Areas

Other Undisclosed Autoimmune Indication Drugs